Skip to content
Stop using now Drug recall · FDA · Published March 23, 2015

Mylan Gemcitabine Recall: Particulate Matter Hazard

Mylan recalls 2,455 vials of Gemcitabine for Injection due to particulate matter. Check lot numbers 7801221 and 7801222.

🇺🇸 FDA recall #D-1333-2015DrugMylan ›
Take action

Contact the company

Recalling firmMylan Institutional LLC4901 Hiawatha Dr · Rockford, IL 61103-1287
✎ GovInfoNow plain-language explainer

Mylan Institutional LLC is recalling a specific batch of Gemcitabine for Injection, USP (2 g/vial) because the lyophilized powder contains visible particulate matter. This Class I recall affects 2,455 vials distributed nationwide and in Puerto Rico. The record does not specify what actions healthcare providers or patients should take regarding these vials. Read more at govinfonow.com/recall/44829-mylan-institutional-llc-recalls-gemcitabine-for-injection-usp-2-g.

Source Summary by GovInfoNow · govinfonow.com/recall/44829-mylan-institutional-llc-recalls-gemcitabine-for-injection-usp-2-g · Updated October 12, 2026 · FDA enforcement record: FDA #D-1333-2015

Cite this page

“Mylan Gemcitabine Recall: Particulate Matter Hazard.” GovInfoNow, updated October 12, 2026. https://govinfonow.com/recall/44829-mylan-institutional-llc-recalls-gemcitabine-for-injection-usp-2-g. Based on FDA recall #D-1333-2015 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1333-2015%22&limit=1).

The FDA announced on March 23, 2015, that Mylan Institutional LLC is recalling Gemcitabine for Injection, USP vials due to the presence of particulate matter. Owners should stop using the product and contact Mylan for a refund.

How to tell if you have it

  • Gemcitabine for Injection, USP, 2 g*/vial, Lyophilized powder in a Single-Use Vial
  • NDC 67457-463-02
  • UPC 3 67457 46302 5
  • Lot #: 7801221, 7801222
  • Expiration: 03/16

The hazard

The recall is due to the presence of particulate matter in the vials. The FDA classified this as a Class I recall, indicating a high risk of adverse health consequences.

Context

GovInfoNow's records show Mylan Institutional LLC has 10 other recalls on record since January 23, 2015. Other recent recalls include the Mylan Thiamine HCl Injection recall (May 3, 2021), the Mylan Amiodarone Injection recall (August 17, 2020), and the Mylan Daptomycin Injection recall (July 7, 2020). Other recent recalls of similar products include the IMAAVY Injection recall (September 23, 2026), the Mylan Mycophenolate Mofetil Injection recall (July 2, 2026), and the GE Healthcare Omnipaque 300 mg/mL Injection recall (March 24, 2026).

How to tell if you have this one

Check if you have Gemcitabine for Injection, USP, 2 g/vial, Lyophilized powder in a Single-Use Vial manufactured by Mylan Institutional LLC. Look for NDC 67457-463-02 and UPC 3 67457 46302 5. The affected lots are 7801221 and 7801222, with an expiration date of 03/16.

  • Brand
    Mylan
  • Product
    Gemcitabine for Injection, USP, 2 g*/vial, Lyophilized powder in a Single-Use Vial, Rx only, Manufactured for: Mylan
  • Category
    Drug
FDA recall event · 3 products

All 3 products in this recall

FDA lists each product line separately under one recall event. Check your product description, lot or code numbers against each row. Every row shares the hazard and remedy on this page.

  • Classification
    Class I
  • Status
    Terminated
  • Distribution
    Nationwide and Puerto Rico
Recall numberProduct, codes & lotsQuantity
D-1332-2015Gemcitabine for Injection, USP, 200 mg*/vial, Lyophilized powder in a Single-Use Vial, Rx only, labeled as a) Manufactured for: Mylan Institutional LLC, Rockford, IL 61103, Made in India, NDC 67457-464-20, UPC 3 67457 46420 6; and b) Distributed by Pfizer Labs, Division of Pfizer Inc, New York, NY 10017, Made in India, NDC 0069-3857-10, UPC 3 00693 85710 4.; Lot #: a) 7801396, 7801398, 7801401, 7801406, Exp 08/16; 7801427, Exp 09/16; b) 7801089, 7801084, Exp 07/15; 7801110, Exp 08/15a) 35,197 vials; b) 21,302 vials
D-1333-2015Gemcitabine for Injection, USP, 2 g*/vial, Lyophilized powder in a Single-Use Vial, Rx only, Manufactured for: Mylan Institutional LLC, Rockford, IL 61103, Made in India, NDC 67457-463-02, UPC 3 67457 46302 5.; Lot #: 7801221, 7801222, Exp 03/162,455 vials
D-1334-2015Gemcitabine for Injection, USP, 1 g*/vial, Lyophilized powder in a Single-Use Vial, Rx only, Manufactured for: Mylan Institutional LLC, Rockford, IL 61103, Made in India, NDC 67457-462-01, UPC 3 67457 46201 1.; Lot #: 7801273, 7801284, Exp 05/1610,094 vials
Based on the official FDA remedy

What to do — step by step

  1. Inspect Inventory

    Check your stock for Gemcitabine vials with NDC 67457-463-02 and lot numbers 7801221 or 7801222.

  2. Verify Product Details

    Confirm the product is the 2 g/vial Lyophilized powder manufactured for Mylan Institutional LLC.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFLPuerto Rico: yesPR

FDA distribution: “Nationwide and Puerto Rico” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 14 months after the firm started it.

1. Firm started the recall: Mar 23, 201512. FDA classified it Class I: Aug 14, 201523. Published in FDA’s Enforcement Report: Aug 26, 201534. FDA terminated the recall: May 20, 2016420152016
  1. Firm started the recall
  2. FDA classified it Class I
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-1333-2015 (March 23, 2015) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-1333-2015 to see it in context.
  • Plain-language summary written by qwen3.6:35b-a3b on October 12, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA